| Patient | Benjamin Franklin |
|---|---|
| Date of birth | 1950-01-17 |
| Identifiers | MRN HR-EN004-SYN; SSN (made up) 000-04-3318 |
| Document date | 2026-05-18 |
| Author | Lydia Penhallow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review four weeks after stone removal and prostate resection. [S]
Mr. Franklin returns four weeks after transurethral laser cystolitholapaxy and resection of the prostate. The catheter came out on the second day after surgery. His stream is strong, he gets up once at night, and he has had no pain or blood in the urine for two weeks. Stone analysis showed pure uric acid. He has had no gout flare on allopurinol 200 mg and colchicine. The planned urate check two to five weeks after the dose increase was not done, because his surgery fell in that window. He completed a 24-hour urine collection yesterday. He drinks about 1.5 L a day and finds it hard to drink more. Tamsulosin was stopped at surgery. [S]
| Element | Detail |
|---|---|
| Surgery | Cystolitholapaxy and transurethral resection four weeks ago; uncomplicated |
| Stone analysis | 100 percent uric acid |
| Urinary symptoms | Strong stream, nocturia once, no pain or blood for two weeks |
| Gout | No flare on allopurinol 200 mg and colchicine |
| Fluids | About 1.5 L a day |
| Medicines stopped | Tamsulosin at surgery |
| System | Result | Finding |
|---|---|---|
| Genitourinary | Negative | No dysuria, hematuria, or incontinence; nocturia once |
| Musculoskeletal | Negative | No joint pain; no muscle aches on atorvastatin |
| Constitutional | Negative | No fever since surgery |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2019-05-06 to 2026-03-02 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 | active | S |
| Allopurinol 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 to 2026-03-30 | completed | S |
| Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth daily | Two tablets by mouth daily | Oral route | 2026-03-30 to 2026-05-18 | completed | S |
| Allopurinol 300 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-05-18 | active | S |
| Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis | One tablet by mouth daily | Oral route | 2026-03-02 to 2026-09-14 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 2026-03-02 | active | S |
| Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime until surgery | One capsule by mouth at bedtime | Oral route | 2026-03-30 to 2026-04-20 | completed | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-30 | active | S |
| Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2026-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-18 | Body height | 175 | cm | S |
| 2026-05-18 | Body weight | 94.6 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 30.9 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 72 | /min | S |
| 2026-05-18 | Respiratory rate | 16 | /min | S |
| 2026-05-18 | Body temperature | 36.7 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-18 | Urate [Mass/volume] in Serum or Plasma | 6.4 | mg/dL | 3.5-7.2 mg/dL | Normal | S |
| 2026-05-18 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-18 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-18 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-05-18 | Urea nitrogen [Mass/volume] in Serum or Plasma | 20 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-05-18 | Creatinine [Mass/volume] in Serum or Plasma | 1.31 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-05-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 56 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-05-18 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-05-18 | pH of Urine | 5.3 | [pH] | 4.5-8 [pH] | Normal | S |
| 2026-05-18 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 1 | /[HPF] | <=2 /[HPF] | Normal | S |
| 2026-05-18 | Volume of 24 hour Urine | 1.45 | L/(24.h) | At least 2.5 L a day for stone prevention | Low | S |
| 2026-05-18 | Urate [Mass/time] in 24 hour Urine | 840 | mg/(24.h) | <=800 mg/(24.h) | High | S |
| 2026-05-18 | Citrate [Mass/time] in 24 hour Urine | 410 | mg/(24.h) | >=320 mg/(24.h) | Normal | S |
| 2026-05-18 | Calcium [Mass/time] in 24 hour Urine | 180 | mg/(24.h) | <=250 mg/(24.h) | Normal | S |
| 2026-05-18 | US Urinary bladder Volume post void | 35 | mL | <=100 mL | Normal | S |
| 2026-05-18 | International Prostate Symptom Score [IPSS] | 6 | {score} | S |
Vital signs recorded on 2026-05-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Abdomen | No suprapubic tenderness; bladder not palpable |
| Joints | No synovitis or tophi |
| Cardiovascular | Regular rhythm; no edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Gout with recurrent flares, mostly in the right big toe, without tophi; synthetic modern diagnosis linked to his documented gout | active | confirmed | M1A.0710 | S — Synthetic modern diagnosis; his recurrent gout is documented in his own letters (D). |
| Bladder stone (2.6 cm, uric acid on analysis) with bladder outlet obstruction, removed by cystolitholapaxy; synthetic modern diagnosis linked to his documented stone | resolved | confirmed | N21.0 | S — Synthetic modern diagnosis confirmed by CT and cystoscopy; his stone is documented in his own letters (D), though its composition is not known. |
| Chronic kidney disease stage G3a A1 | active | confirmed | N18.31 | S — Synthetic diagnosis; no measure of kidney function from his lifetime exists. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime exists. |
| Benign prostatic hyperplasia with lower urinary tract symptoms and bladder outlet obstruction, treated by transurethral resection | active | confirmed | N40.1 | S — Synthetic diagnosis made at the urology consultation as the probable cause of the bladder stone; the cause of his historical stone is not documented. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Serum urate | Every 2 to 5 weeks while titrating; every 6 months once at target | Completed today | 6.4 mg/dL on allopurinol 200 mg; dose increased to 300 mg |
| Laboratory | Serum urate 2 to 5 weeks after raising allopurinol to 200 mg | Once after each dose change | Deferred | Not drawn in the window, a deviation from the protocol; the surgery fell in that period and the check was not rebooked. It is seven weeks today. No harm: no flare, and the dose is raised today. Corrective action: a standing urate order every four weeks until target |
| Medication safety | Flare prophylaxis and allopurinol tolerance | 3 to 6 months; every visit while titrating | Completed today | Colchicine week 11; no rash or muscle symptoms |
| Laboratory | Metabolic evaluation after a stone: 24-hour urine | Once, within 6 months of a stone event | Completed today | Volume 1.45 L, uric acid 840 mg/day, citrate 410 mg/day, calcium 180 mg/day |
| Laboratory | Urinalysis: urine pH and red cells | After stone treatment; with each change in alkalinization | Completed today | pH 5.3; red cells 1 per high-power field, cleared |
| Laboratory | Metabolic panel | With each eGFR draw; after starting potassium-affecting therapy | Completed today | Potassium 4.5 mmol/L, creatinine 1.31 mg/dL, eGFR 56 |
| Examination | Office and home blood pressure | Every visit | Completed today | 132/78 mmHg |
| Survey | IPSS | Every follow-up; 1, 3, 6, and 12 months after a procedure | Completed today | 6, down from 16 |
| Examination | Post-void residual after the procedure | Post-procedural follow-up | Completed today | 35 mL |
| Imaging | Imaging for hematuria | Only if hematuria persists after the stone is treated | Not indicated | Hematuria cleared and cystoscopy showed no tumor |
| Medication safety | Medication review for NSAIDs and dose adjustment | Every visit | Completed today | No NSAIDs; tamsulosin stopped at surgery |
| Self-management | Fluid intake | Every visit | Completed today | About 1.5 L a day, below the goal; measuring jug advised |
Goal progress:
Guideline basis: 2020 American College of Rheumatology Guideline for the Management of Gout (2020); Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019); EAU Guidelines on Urolithiasis (including bladder stones) (2025); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026)
Follow-up: Potassium and serum urate in 2 to 5 weeks. Gout, stone, kidney, and blood pressure review in about four months. Next scheduled visit 2026-09-14: gout, stone prevention, kidney, and blood pressure review at about six months. [S]